Skip to content

Symptom Clusters in Children With Exacerbation-prone Asthma

Symptom Clusters in Children With Exacerbation-prone Asthma

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04002362
Enrollment
68
Registered
2019-06-28
Start date
2019-11-13
Completion date
2025-12-24
Last updated
2026-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma in Children

Keywords

Asthma, Pediatrics

Brief summary

Pediatric participants with exacerbation-prone asthma will receive an intramuscular injection of triamcinolone acetonide and will be followed for 48 weeks. The study visit 2 weeks after the injection will assess the response to the study medication, while the remaining study visits will examine the temporal stability of the symptom clusters.

Detailed description

Asthma symptom control is suboptimal in the majority of children in the United States, despite widespread availability of asthma controller medications and standardized treatment guidelines. While deaths from asthma have declined, 53.7% of children with asthma continue to experience an exacerbation each year and the associated public health burden is substantial. While the factors responsible for poor asthma symptom control are complex and include limited access to care, poor adherence to preventative asthma medications, and exposures to environmental allergens and irritants such as tobacco smoke, it is also recognized that children with exacerbation-prone asthma are a heterogeneous group with differing clinical outcomes and longitudinal disease trajectories. Symptoms (defined as subjective sensations) can also be quite varied within and among affected children. Whereas some children have persistent, troublesome respiratory symptoms, others have respiratory symptoms only with upper respiratory infections. Mental health symptoms and social health symptoms have been inadequately characterized in this population, but some children with asthma also report depression and anxiety and impaired family functioning and relationships that may further worsen asthma outcomes. However, prior studies are limited by a narrow focus on individual symptoms in isolation. To date, there has been no attempt to identify symptom clusters (defined as two or more concurrent symptoms independent of other clusters) in children with exacerbation-prone asthma. Poor understanding of symptom clusters is a major shortcoming in asthma symptom science. In other chronic disorders such as cancer, compared with a single symptom, symptom clusters of pain, fatigue, sleep disturbance and mood disturbance significantly worsen patient-reported outcomes of functional status and quality of life. There is also emerging evidence that interventions for one symptom within a cluster (i.e., cognitive-behavioral therapy for pain) reduce the severity of other symptoms within that cluster (i.e., fatigue and sleep disturbance). Because children with exacerbation-prone asthma rarely report a single symptom, greater knowledge of the assessment (and ultimately management) of symptom clusters in these children has the potential to significantly improve individualized treatment and clinical outcomes. The researchers propose a 48-week cohort study to test the overarching hypothesis that symptom clusters and their associated inflammatory and metabolic pathways predict corticosteroid treatment responsiveness (primary objective outcome) and quality of life (patient-reported secondary outcome) in children 6- 21years of age with exacerbation-prone asthma. Participants will be given the option to either: 1) complete a single study visit, with telephone/email contacts and a review of their electronic medical record for up to 48 weeks after enrollment, or 2) complete the 48-week cohort study with scheduled study visits. Participants who select option 2 with follow-up over 48 weeks will also have the option to complete visits 3, 4 and 5 by telephone.

Interventions

DRUGTriamcinolone Acetonide

An intramuscular injection of triamcinolone acetonide (1 mg/kg, up to 40 mg maximum) is administered deep in the gluteal muscle by a trained registered nurse.

Sponsors

Emory University
Lead SponsorOTHER
National Institute of Nursing Research (NINR)
CollaboratorNIH

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
6 Years to 21 Years
Healthy volunteers
No

Inclusion criteria

* Age 6 to less than 21 years at the enrollment visit * Physician diagnosis of asthma * History of an asthma exacerbation in the previous 12 months, defined as either: * Treatment with systemic corticosteroids, or * Increase in rescue medication use (i.e., albuterol or inhaled corticosteroid) for 24 hours or more, or * One or more missed school days due to asthma symptoms, or * An unscheduled visit for asthma at either a physician's office, urgent care, hospital emergency room, or * Hospitalization for asthma

Exclusion criteria

* Previous allergic reaction to systemic corticosteroids * Hepatic, biliary, or renal disease that can interfere with drug metabolism/excretion * Chronic medical disorders that may increase the risk of drug-related injury, including osteogenesis imperfecta (increased risk of fracture with corticosteroids), or Crohn's disease, ulcerative colitis, juvenile rheumatoid arthritis, clotting disorders, or Factor deficiency (increased risk of bleeding with corticosteroid therapy) * Pregnancy * Current smoking * Congenital disorders or deformities of the chest wall, lungs or airways * History of premature birth \<35 weeks gestation * Unwillingness to receive triamcinolone * Planning to relocate before study completion

Design outcomes

Primary

MeasureTime frameDescription
Change in Asthma Control Questionnaire (ACQ) ScoreBaseline, Day 14Responsiveness to the study treatment is assessed with the Asthma Control Questionnaire (ACQ). This 7-item questionnaire includes questions related to daytime and nocturnal symptoms, short-acting bronchodilator use, and lung function during the clinic visit on that day. Participants report how difficult their asthma was to control on a scale from 0 (no impairment) to 6 (maximum impairment). Total raw scores range from 0 to 42, with higher scores indicating poorer asthma control. Responsiveness to treatment is determined with the mean difference in ACQ score the baseline visit and the Day 14 visit, with a reduction of 0.5 considered a minimally important difference.

Secondary

MeasureTime frameDescription
Patient-Reported Outcomes Measurement Information System (PROMIS) Pediatric Asthma Impact Scale (PAIS)Weeks 16, 32, and 48Quality of life is assessed with the 8-item PAIS instrument. As with all PROMIS measures, the PAIS is scored on the T-score metric, with higher scores reflecting more of the concept being measured. On the T-score metric, 50 is the mean of the reference population and 10 is the standard deviation, thus, scores of 40 and 60 are one standard deviation lower and higher than the mean of the reference population, respectively.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORAnne Fitzpatrick, PhD

Emory University

Participant flow

Recruitment details

Participants were recruited from the Emory Children's Center and Children's Healthcare of Atlanta in Atlanta, Georgia, USA. Participant enrollment began November 13, 2019 and all follow-up assessments for the Day 14 time point were completed by January 16, 2025. Follow-up assessments for the Week 48 time point were completed by December 24, 2025..

Baseline characteristics

Characteristic
Age, Categorical
<=18 years
66 Participants
Age, Categorical
>=65 years
0 Participants
Age, Categorical
Between 18 and 65 years
2 Participants
Age, Continuous10.6 years
STANDARD_DEVIATION 3.7
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
68 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
2 Participants
Race (NIH/OMB)
Black or African American
50 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
16 Participants
Region of Enrollment
United States
68 Participants
Sex: Female, Male
Female
26 Participants
Sex: Female, Male
Male
42 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 68
other
Total, other adverse events
0 / 68
serious
Total, serious adverse events
0 / 68

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026